March 27, 2026 06:23 ET | Source: Novo Nordisk A/S Novo Nordisk A/S
Articles of Association for Novo Nordisk A/S 2026
Attachment
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
Novo Nordisk commits USD 200 million over 10 years to help the World Diabetes Foundation strengthen diabetes prevention and care in underserved communities
